Unknown

Dataset Information

0

Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas.


ABSTRACT: LESSONS LEARNED:The combination of cisplatin, docetaxel, and erlotinib as frontline treatment for recurrent and/or metastatic head and neck squamous cell carcinomas led to a response rate of 62%.This result exceeded the prespecified target response rate of 50% and represented an improvement compared with historical controls.This regimen warrants further investigation. BACKGROUND:The epidermal growth factor receptor (EGFR) plays a key role in the carcinogenesis of head and neck squamous cell carcinomas (HNSCC). We conducted this clinical study to test the hypothesis that the addition of erlotinib to first-line cisplatin and docetaxel for patients with recurrent and/or metastatic HNSCC would yield a response rate of at least 50%, representing an improvement from historical controls. METHODS:Patients with recurrent and/or metastatic HNSCC, with at least one measurable lesion, no prior chemotherapy for recurrent and/or metastatic disease, prior combined modality therapy completed >6 months before enrollment, and performance status ≤2 were treated with cisplatin, docetaxel, and erlotinib for up to six cycles, followed by maintenance erlotinib until disease progression. The primary endpoint was response rate. RESULTS:Fifty patients were enrolled (42 male, 12 never smokers, 19 with oropharynx cancer). The median number of cycles was five; 31 patients initiated maintenance erlotinib; 14 patients required erlotinib dose reductions. The objective response rate was 62%, and the median progression-free and overall survival were 6.1 and 11.0 months, respectively. Toxicity profiles were consistent with the known side effects of the study drugs. CONCLUSION:The study met its primary endpoint and improved response rates compared with historical controls. The findings support further evaluation of the regimen for recurrent and/or metastatic HNSCCs.

SUBMITTER: William WN 

PROVIDER: S-EPMC5947451 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas.

William William N WN   Tsao Anne S AS   Feng Lei L   Ginsberg Lawrence E LE   Lee J Jack JJ   Kies Merrill S MS   Glisson Bonnie S BS   Kim Edward S ES  

The oncologist 20180125 5


<h4>Lessons learned</h4>The combination of cisplatin, docetaxel, and erlotinib as frontline treatment for recurrent and/or metastatic head and neck squamous cell carcinomas led to a response rate of 62%.This result exceeded the prespecified target response rate of 50% and represented an improvement compared with historical controls.This regimen warrants further investigation.<h4>Background</h4>The epidermal growth factor receptor (EGFR) plays a key role in the carcinogenesis of head and neck squ  ...[more]

Similar Datasets

| S-EPMC3835153 | biostudies-literature
| S-EPMC11831104 | biostudies-literature
| S-EPMC8834318 | biostudies-literature
| S-EPMC4855241 | biostudies-literature
| S-EPMC2768532 | biostudies-literature
| S-EPMC4701554 | biostudies-literature
| S-EPMC4811141 | biostudies-literature
| S-EPMC8440813 | biostudies-literature
| S-EPMC3805493 | biostudies-literature
2009-03-12 | GSE12020 | GEO